Core Viewpoint - The company, Olin Bio (688319.SH), has announced the initiation of Phase III clinical trials for its quadrivalent influenza virus split vaccine, marking a significant advancement in its vaccine development efforts [1] Group 1: Clinical Trial Details - The Phase III clinical trial has commenced with the enrollment of the first subject [1] - The vaccine is intended for individuals aged 6 months and older to prevent influenza caused by vaccine-related virus strains [1] - The trial employs a randomized, blinded, positive control design to further evaluate the vaccine's efficacy and safety [1] Group 2: Strategic Importance - The influenza vaccine series is a key focus area for the company within the viral vaccine sector [1] - The initiation of this clinical trial signifies an important breakthrough for the company in the viral vaccine field [1] - This development is expected to enhance the company's research pipeline and diversify its product offerings [1]